Nanocarriers for delivery of siRNA as gene silencing mediator

Authors

  • Aideé Morales-Becerril Laboratorio de Toxicología y Farmacia, Facultad de Química, Universidad Autónoma del Estado de México, Toluca, Estado de México 50120, México https://orcid.org/0000-0003-0755-7680
  • Liliana Aranda-Lara Laboratorio de Investigación en Teranóstica, Facultad de Medicina, Universidad Autónoma del Estado de México, Toluca, Estado de México 50180, México https://orcid.org/0000-0003-4066-2327
  • Keila Isaac-Olivé Laboratorio de Investigación en Teranóstica, Facultad de Medicina, Universidad Autónoma del Estado de México, Toluca, Estado de México 50180, México https://orcid.org/0000-0003-4388-3811
  • Blanca E. Ocampo-García Laboratorio Nacional de Investigación y Desarrollo de Radiofarmacos-CONACyT, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac, Estado de México 52750, México https://orcid.org/0000-0002-5831-8412
  • Enrique Morales-Avila Facultad de Química, Universidad Autónoma del Estado de México, Paseo Tollocan esq Paseo Colón S/N., Toluca, Estado de México. C.P. 50120, México. Tel. + (52) (722) 2 17 41 20, Fax. + (52) (722) 2 17 38 90, E-mail: enrimorafm@yahoo.com.mx or emoralesav@uaemex.mx https://orcid.org/0000-0001-8471-6791

DOI:

https://doi.org/10.17179/excli2022-4975

Keywords:

siRNA, nanocarrier, drug delivery systems, nanomedicine

Abstract

The term nanocarrier refers to sub-micrometric particles of less than 100 nm, designed to transport, distribute, and release nanotechnology-based drug delivery systems. siRNA therapy is a novel strategy that has great utility for a variety of treatments, however naked siRNA delivery has not been an effective strategy, resulting in the necessary use of nanocarriers for delivery. This review aims to highlight the versatility of carriers based on smart drug delivery systems. The nanocarriers based on nanoparticles as siRNA DDS have provided a set of very attractive advantages related to improved physicochemical properties, such as high surface-to-volume ratio, versatility to package siRNA, provide a dual function to both protect extracellular barriers that lead to elimination and overcome intracellular barriers limiting cytosolic delivery, and possible chemical modifications on the nanoparticle surface to improve stability and targeting. Lipid and polymeric nanocarriers have proven to be stable, biocompatible, and effective in vitro, further exploration of the development of new nanocarriers is needed to obtain safe and biocompatible tools for effective therapy.

Downloads

Published

2022-08-01

How to Cite

Morales-Becerril, A., Aranda-Lara, L., Isaac-Olivé, K., Ocampo-García, B. E., & Morales-Avila, E. (2022). Nanocarriers for delivery of siRNA as gene silencing mediator. EXCLI Journal, 21, 1028–1052. https://doi.org/10.17179/excli2022-4975

Issue

Vol. 21 (2022)

Section

Review articles

Categories

License

Copyright (c) 2022 Aideé Morales-Becerril, Liliana Aranda-Lara, Keila Isaac-Olivé, Blanca E. Ocampo-García, Enrique Morales-Avila

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).